The 
Cell invasion through the extracellular matrix (ECM) is a driving force for tissue development and cancer metastasis (1, 2) . Invading cells possess ECM degrading proteolytic enzymes that appear at unique surface structures, which we have termed invadopodia (3) . The factors that promote protease localization at sites of cell invasion are not known. However, increasing evidence indicates that tumor cell invasion involves the accumulation of membrane-bound proteases that direct activation of workhorse enzymes such as the 72-kDa matrix metalloprotease (MMP), MMP-2, on the cell surface (2) (3) (4) (5) . Surface activation of MMP-2 can be stimulated by cultivation of cells on collagen (6) or gelatin (7), or treatment with concanavalin A (Con A) (8) . Such activation is sensitive to synthetic MMP inhibitors (9) (10) (11) and tissue inhibitor of MMP 2 (TIMP-2) (12) . Recent studies showed that MMP-2 activation is mediated by membrane type 1 MMP (MT-MMP) in the capacity of either an activator (12) (13) (14) or a receptor (15) . MT-MMP is constitutively activated by a furin-like pathway, and may also directly degrade ECM (16) (17) (18) . Thus, it is possible that MT-MMP functions both in MMP-2 activation, and in localizing such proteases to sites of cell invasion.
A limitation of biochemical analysis of MMP-2 activation by MT-MMP is that the degradative and invasive activities of the cell can be compared only to the relative amount of proteases or activators present, whereas its correlation with the most relevant parameter of cell invasion-the cellular site of protease activation and action-remains unknown. Cell surface proteolytic activity has been identified at specialized membrane extensions, invadopodia, of a moderately invasive RPMI-7951 human melanoma cell line (19) . We have expressed full-length and mutant MT-MMP cDNAs in RPMI-7951 cells and examined the activation of soluble and ECMbound MMP-2 as well as the degradative and invasive activities of the transfected cells. Proteolytic activity of soluble and ECM-bound MMP were measured to assess sites of protease action. We show here that overexpression of the membranebound protease activator MT-MMP resulted in localization of proteases at invadopodia, and initiated a proteolytic cascade for cell invasion. Furthermore, we demonstrated that the transmembrane (TM)͞cytoplasmic domain of MT-MMP (TM MT-MMP , 542 VVLPVLLLLLVLAVGLAVFFFRRHGT-PRRLLYCQRSLLDKV 582 ) was required for invadopodial localization of the enzyme and therefore for directing cellular invasion, as neither occurred with MT-MMP mutants lacking the TM MT-MMP (⌬TM MT-MMP ) or containing the interleukin 2 receptor ␣ chain (IL-2R) TM IL-2R (⌬TM MT-MMP ͞TM IL-2R ).
MATERIALS AND METHODS

Materials.
The human melanotic melanoma RPMI-7951 (ATCC HTB 66) was purchased from the American Type Culture Collection. Mouse mAb 113-5B7 directed against MT-MMP (13) was kindly provided by K. Iwata (Fuji). Mouse antibody 7-6C1 against TIMP-1 was purchased from Oncogene Science. The metalloprotease inhibitor CT1847 (20) was kindly provided by A. Docherty (Celltech, Slough, U.K.).
Cell Culture and in Vitro Degradation͞Invasion Assays. RPMI-7951 cells were cultured in a 1:1 mixture of DMEM and RPMI medium 1640 supplemented with 10% calf serum, 5% Nu-serum (Collaborative Research), 2 mM L-glutamine, 1 unit͞ml penicillin, and 10 g͞ml streptomycin as described (21) . RPMI-7951 is a moderately invasive human melanoma cell line, secreting 72 kDa MMP-2, which converts to 64-and 62-kDa forms when activated, and expressing background level of membrane proteases (19) . For the fibronectin degradation͞ invasion assay, cells transfected with MT-MMP and its mutants were collected by trypsinization and 10 5 cells were added to fluorescein-fibronectin-coated crosslinked gelatin films on a 15-mm round glass coverslip in a 12-well plate as described (19, 22) . This technique measures the fibronectin degradation by cells as well as the invasiveness in terms of foci of invadopodial extensions and surface indentations in the crosslinked gelatin film. For the former, cells were allowed to grow on the films for the indicated times, photographed using the Planapo 63͞1.4 or 25͞1.2 objectives on a Zeiss Photomicroscope III under epifluorescence, and digitized from photographic negatives using Optimas image analyzer coupled to a Panasonic WV-CD50 camera. For the latter, cells that had been cultured on fibronectin-gelatin films for 12 h were analyzed for the appearance of invadopodial extensions into the crosslinked gelatin film using Nomarski Differential Contrast microscopy as described (19) . In the case of treatment with Con A (25 g͞ml) (8) or protease inhibitors, cells were allowed to attach to fluorescent fibronectin-coated, crosslinked gelatin films in complete medium at 37°C for 1 h, and then incubated in experimental conditions (serum-free DMEM, Con A, or inhibitors indicated in the figure legends), for additional 5 h. For visualizing MT-MMP or TIMP-1 localization, transfected cells were allowed to spread on fluorescein-fibronectin-coated crosslinked gelatin films for 3 h, and stained with mouse mAb 113-5B7 against MT-MMP or mouse mAb 7-6C1 against TIMP-1 (Oncogene Science) at 37°C for 30 min, fixed with cold 95% acetone for 5 min, and developed with tetramethylrhodamine B isothiocyanate-goat anti-mouse IgG (10 g͞ml; Cappel) as described (23) .
Vector Construction and Transfection of RPMI-7951 Cells. The pSG5 plasmids for expression of wild-type MT-MMP, ⌬TM MT-MMP , and the chimera: ⌬TM MT-MMP ͞TM IL-2R , TIMP-1͞TM MT-MMP , and TIMP-1͞TM IL-2R , were constructed by manipulating the cDNAs of these proteins as described (23) . Cells were transfected with pSG5 plasmid lacking an insert (Mock) or containing sequences encoding MT-MMP or other mutant proteins above using LipofectAMINE method (Life Technologies, Grand Island, NY). Transfected cells were cultured for 48 h and suspended by trypsin͞EDTA for in vitro degradation͞invasion assay or immunofluorescence as described above. To verify that MT-MMP or recombinant proteins were expressed in transfected cells, cells were examined by indirect immunofluorescence staining or by a combination of cell surface biotinylation and immunoprecipitation as described (23) . Among these proteins, only ⌬TM MT-MMP was detected in the culture medium conditioned by ⌬TM MT-MMPtransfected cells, whereas MT-MMP and other chimeric proteins were localized on the cell surface. Subcellular Fractionation. Fractionation was performed as described (24) . Cell bodies were sheared from adherent cells using an ''L'' shaped Pasteur pipette. Proteins associated with invadopodia and the ECM were extracted by collecting the gelatin substratum and solubilizing proteins within it using RIPA buffer (1% Nonidet P-40͞0.5% sodium deoxycholate͞ 0.1% SDS in TBS, pH 8.0.).
Gelatin Zymography for Visualizing MMP-2 Activation. The serum-free medium conditioned by transfected cells, or cells treated with Con A or protease inhibitors, was collected from Ϸ10 6 cells after 2 days of growth. Conditioned medium was centrifuged (1,000 ϫ g for 10 min) to remove any cellular debris. Aliquots from the medium, or cell lysate or invadopodia͞ECM extract described above were solubilized in SDS͞ PAGE sample buffer and analyzed by gelatin zymography as described (8) .
RESULTS
To investigate the biological consequences of MT-MMP expression, RPMI-7951 cells were transfected with MT-MMP or a vector control, collected by trypsinization and plated on f luorescein-fibronectin-coated crosslinked gelatin films. Within 1-3 h, cells transfected with full-length MT-MMP initiate localized fibronectin͞gelatin degradation in association with invadopodia at the leading edge of the cell ( gelatin films (Fig. 1 C and D) whereas nontransfected cells and controls did not ( Fig. 1 E and F) . To confirm MT-MMP expression by transfected cells, mAb 113-5B7 was used to immunoprecipitate proteins from surface biotinylated cells. A 63-kDa protein, the expected size for mature MT-MMP, was immunoprecipitated from a lysate of RPMI-7951 cells transfected with MT-MMP, but very little protein was immunoprecipitated from the parental cell line lysate (Fig. 1G ). These results demonstrate that MT-MMP is a key cell surface protease involved in degradation of the ECM at invadopodia.
To determine whether activation of MMP-2 can lead to matrix degradation, RPMI-7951 cells transfected with MT-MMP or treated with Con A were analyzed for gelatinase activation, fibronectin͞gelatin degradation, and invasion. Conditioned medium and cell lysate from cells transfected with full-length MT-MMP or treated with Con A contained the 64-and 62-kDa active forms of MMP-2, while that of parental and mock transfected cells contained the latent 72-kDa form (Fig.  2A) . The activation mediated by MT-MMP transfection was blocked by the synthetic matrix metalloprotease inhibitor CT1847, and was not sensitive to inhibitors of serine, cysteine, or aspartate proteases (Fig. 2B) . RPMI-7951 cells overexpressing MT-MMP degraded more fibronectin͞gelatin film than their counterparts transfected with vector alone (mock cells), parental cells treated with Con A (Fig. 2C) , or MT-MMP expressing cells treated with Con A (Fig. 2D) . In 6-12 h, mock-transfected cells exhibited similar fibronectin͞gelatin degradation patterns to Con A treated cells, i.e., very few degradation spots (Fig. 2 C and D) . In contrast, cells expressing MT-MMP began to degrade the fibronectin͞gelatin substratum within 3 h of plating, and digested most of the fibronectin͞ gelatin after 12 h (Fig. 2C, MT-MMP) . When this increase in fibronectin degradation was quantified, we found that significantly more fibronectin substratum ( Ͻ 1 ϫ 10 Ϫ5 ) was removed by MT-MMP transfected cells compared with mock cells, or either mock or MT-MMP transfected cells treated with Con A (Fig. 2D) . The enhanced fibronectin degradation by MT-MMP transfected cells paralleled their subsequent increase in invasion into the crosslinked gelatin film (Fig. 2 E) , as measured by percentage of cells extending their invadopodia into the film ( Ͻ 1 ϫ 10 Ϫ5 ). Consistent with the inhibition of MMP-2 activation by the metalloprotease inhibitor CT1847 (Fig. 2B) , the fibronectin degradation by MT-MMP overexpressing cells was also inhibited by CT1847 but not by other protease inhibitors (Fig. 2F) . These data suggest that MMP-2 activation is necessary but not sufficient for localized fibronectin degradation and directed invasion.
A previous study has shown that the TM MT-MMP could function as a membrane linker when fused to TIMP-1, and that a chimera of MT-MMP and the TM IL-2R was retained on the cell surface and activated MMP-2 (23). We tested here the role of the TM MT-MMP in localization to invadopodia and in the degradation͞invasion phenotype of melanoma cells. During cell invasion, structures described as ''invadopodial complexes'' are formed (25) . Such structures appear to represent immature invadopodia at the leading edge of the cell in close contact with the matrix (Fig. 1 A and B) , and they extend to form the invasion front of the cell. Immunofluorescent staining using mAb 113-5B7 shows that MT-MMP is predominantly associated with invadopodial complexes at the leading edge of a transfected cell (Fig. 3A) , corresponding to the areas where fibronectin͞gelatin degradation occurs (Fig. 3B) . Cells overexpressing full-length MT-MMP localized the molecule at invadopodial complexes (Fig. 3C) as demonstrated by colocalization with the invadopodial marker A27 (25) (Fig. 3D) . However cells transfected with vector pSG5 showed no such invadopodial MT-MMP staining (data not shown). Con A treatment of MT-MMP transfected RPMI-7951 cells significantly reduced their ability to degrade fibronectin͞gelatin and their invasive behavior (Fig. 2 C-E) , but did not affect their ability to activate MMP-2 (Fig. 2 A) . Immunostaining showed that Con A treatment abolished MT-MMP localization to invadopodia as MT-MMP was aggregated on cell surfaces other than A27 labeled invadopodia (Fig. 3 E and F) . To assess the role of various domains of MT-MMP in the invadopodial localization, we used a variety of deletion mutants as well as chimeras formed between TM MT-MMP or TM IL-2R and the extracellular domain of MT-MMP or a secreted protein, TIMP-1. Invadopodial localization was seen in a chimeric TIMP-1 mutant with the TM MT-MMP (Fig. 3G) . However, invadopodial localization of MT-MMP was abolished by truncation of the TM domain (data not shown), and was not seen in a chimera of ⌬TM MT-MMP and the TM IL-2R (Fig. 3 H) . These results show that the TM MT-MMP is critical for mediating invadopodial localization.
Similar to cells treated with Con A or transfected with MT-MMP, the cells transfected with a chimeric ⌬TM MT-MMP͞TM IL-2R mediated activation of MMP-2 into the medium (Fig. 4A) . Cells overexpressing MT-MMP had active MMP-2 associated with invadopodial membranes and the ECM (Fig. 4B) . In contrast cells expressing either ⌬TM MT-MMP or ⌬TM MT-MMP ͞TM IL-2R failed to activate ECM or invadopodia-associated MMP-2 (Fig. 4B) , degrade the fibronectin substratum (Fig. 4C) or to invade the matrix (Fig.  4D) . Mock-transfected cells and cells transfected with ⌬TM MT-MMP , TIMP-1, chimeric TIMP-1͞TM IL-2R , or chimeric TIMP-1͞TM MT-MMP did not activate MMP-2 or degrade͞invade matrix (Fig. 4 A-D) . The fibronectin degradation͞invasion function of MT-MMP was not seen in cells expressing ⌬TM MT-MMP or chimeric ⌬TM MT-MMP ͞TM IL-2R (Fig. 4 C and D) , although these MT-MMP mutants were still retained on the cell surface, and the latter could activate MMP-2 in the medium (Fig. 4 A) . Thus, the TM͞cytoplasmic and catalytic domains of MT-MMP are required for the activation of ECM-bound gelatinase, local ECM degradation and subsequent invasion of melanoma cells.
DISCUSSION
We have shown that overexpression of MT-MMP increases RPMI-7951 human melanoma cell invasion by stimulating invadopodial activity. The membrane-bound protease localizes predominantly to invadopodia that are sites of cellular ECM degradation. Thus, MT-MMP may participate a protease cascade involving enzymes such as seprase and MMP-2 (19, (26) (27) (28) that leads to an increase in melanoma cell invasiveness. We also showed that the TM͞cytoplasmic domain of MT-MMP mediates the spatial organization of MT-MMP to invadopodia and that this is necessary for degradation of the ECM and subsequent invasion. Our data suggest a membrane docking mechanism for melanoma cell invasion in which cell invasiveness can be initiated when active proteases are recruited to sites of ECM degradation.
The biochemical mechanisms by which MMP-2 is involved in invasion are not well-understood. It is known that the secreted MMP-2 can be recruited to tumor cell invadopodia and that it can bind to the ECM (6, 7, 19, (29) (30) (31) . RPMI-7951 cells produce MMP-2 when cultured on the crosslinked gelatin film, and ELISA analysis showed that up to 80% of the proenzyme became bound to crosslinked gelatin films (19) . Also, we showed that active MMP-2 was localized on invadopodia while other matrix-bound and secreted MMP-2 remained latent (6, 19) . In this report, we showed that MT-MMP expression can induce activation of both soluble and ECMbound MMP-2 at sites of invadopodial contact. However, secreted MMP-2 can be activated by cells expressing MT-MMP or ⌬TM MT-MMP ͞TM IL-2R , and by cells treated with Con A (Fig.  2 A and 4A ). Con A treatment significantly ( Ͻ 1 ϫ 10 Ϫ5 ) inhibited the fibronectin͞gelatin degradation (Fig. 2D) and invasion (Fig. 2E) maybe explained by the fact that Con A treatment prevents MT-MMP from localizing to invadopodia (Fig. 3 E and F) . Con A may crosslink membrane glycoproteins, including MT-MMP, on available dorsal cell surfaces, thus the activation of soluble MMP-2 can proceed but localization of MT-MMP to invadopodial complexes is prevented.
In addition to activating MMP-2 (12-14), MT-MMP can serve as a MMP-2 receptor (15) and thus could be involved in the recruitment of the MT-MMP͞MMP-2 complex to sites of invasion. Recent studies showed that MT-MMP may also directly degrade ECM components including fibronectin, collagen and gelatin (16) (17) (18) . Thus, MT-MMP may play dual roles in degrading ECM and in activating matrix-bound proenzyme at invadopodial sites to extend the proteolytic cascade.
RPMI-7951 cells transfected with ⌬TM MT-MMP or chimeric ⌬TM MT-MMP ͞TM IL-2R failed to localize MT-MMP at invadopodia, and were not capable of activating matrix-bound MMP-2, degrading ECM, or invading the matrix. Both MT-MMP and TIMP-1͞TM MT-MMP localized to invadopodia (Fig.  3 C and G) , but only the former coincided with the local fibronectin͞gelatin degradation (Fig. 3 A and B) . These data suggest a model where fibronectin degradation by an invading cell is due to the binding of the TM͞cytoplasmic domain of MT-MMP to an as yet unidentified docking system, resulting in recruitment of the protease into invadopodial complexes. Such colocalization of proteases and matrix substrates will then result in a degradative interaction. We propose that the TM͞cytoplasmic domain of MT-MMP contains specific sequences that are involved in the localization of these proteases to invadopodia contacting the ECM, thus providing a spatially specific mechanism for the regulation of MMP-2 activation, matrix degradation and cellular invasion into the ECM.
